Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A
82.66
CNY
-4.37
(-5.02%)
ISIN
CNE100007D74
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yue Lei Shen
- Full Time Employees
- 1,443
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 12 Baoshen South Street Beijing BE China 210032
- IPO Date
- Sep 1, 2022
- Website
- biocytogen.com
- Similar Companies
- Business
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company principally engaged in the research and development of novel antibody-based drugs and revenue-generating preclinical research services. Founded in 2009 and headquartered in Beijing, China, Biocytogen operates through five main business segments: gene-editing services, preclinical pharmacology and efficacy evaluation, animal models sales, antibody development, and innovative drug development. The company leverages proprietary gene-editing technologies to provide custom gene-targeting services using genetically engineered animal models and cell lines, including over 1,000 drug-targeted humanized models and 800 knockout models under its BioMice™ sub-brand. Its pharmacology platforms support preclinical efficacy and toxicity studies across diverse therapeutic modalities, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), peptides, tumor vaccines, small molecules, CAR-T cell therapies, and oncolytic viruses. Biocytogen serves pharmaceutical and biotechnology companies internationally, with operating facilities in China and the United States. Recently, Biocytogen entered into a strategic collaboration and evaluation agreement with Merck KGaA, Darmstadt, Germany, to advance antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, notably antibody-conjugated lipid nanoparticles (LNPs). This agreement allows Merck KGaA exclusive options to acquire rights to selected antibody assets derived from Biocytogen’s proprietary RenMice® platform, marking a major expansion in Biocytogen’s platform applications beyond traditional antibody therapeutics. The company continues to broaden its innovation in antibody discovery and delivery technologies, reinforcing its strategic focus on next-generation therapeutics and preclinical research solutions. Biocytogen’s business model integrates advanced genetic engineering and preclinical service capabilities, supporting global drug discovery in oncology, immunology, autoimmune, inflammatory, and neurological disorders. With AAALAC-accredited animal facilities in Beijing, Haimen, Jiangsu, and Boston, the company maintains a robust annual production capacity for gene-edited mice and operates over 50 licensing projects for its RenMice® platform worldwide. Overall, Biocytogen Pharmaceuticals (2315.HK) stands as a biotechnology innovator specializing in cutting-edge antibody drug discovery, gene-editing service provision, and comprehensive preclinical pharmacology, focusing on emerging therapeutics and delivery systems to serve multinational pharmaceutical and biotech partners globally. This description incorporates the company's core products and services, geographic operations, founding and headquarters details, and highlights recent strategic collaborations and expansions up to 2025.